Clinical trials: Nervous System Complication
Endometriosis
Pilot Study on a Dietary Supplement With EndoGen™ as Adjunct Therapy in Women With Endometriosis
Current treatments for endometriosis, such as NSAIDs and hormone therapies, are meant for long-term use but often cause side effects, including stomach, liver, heart, and kidney issues; allergies; and hormonal problems like…
- Trial name
- NCT07228975
- Testing
- MetrioFen Gocce
- Where
- 7 sites in Italy
- Volunteers
- 36 people
- Sponsor
- Endok s.r.l.
Sarcoma, Neuroblastoma
To Evaluate the Safety, Activity and Pharmacokinetics of Marqibo in Children and Adolescents With Refractory Cancer
Background: Marqibo(Registered Trademark) is a new anticancer drug. It combines Vincristine sulfate, which is a widely used anticancer drug, and packages it into a tiny fat bubble known as a liposome.
- Conditions
- Sarcoma, Neuroblastoma, Wilms Tumor, Leukemia
- Trial name
- NCT01222780
- Testing
- Marqibo
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Acrotech Biopharma Inc.
Diabetic Neuropathy, Painful
A Study in Participants With Diabetic Peripheral Neuropathic Pain in China
The purpose of this trial is to assess the efficacy of duloxetine 60 milligrams (mg) once daily (QD) compared with placebo, on the change in pain severity from baseline to 12 weeks as measured by the weekly mean of the daily pain…
- Trial name
- NCT01179672
- Testing
- Duloxetine
- Where
- 15 sites in China
- Volunteers
- 405 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Stem Cell Mobilization in Diabetic Neuropathy Subjects Receiving SB-509
The primary and secondary objectives of this study are: Primary: To evaluate stem-cell-mobilization in subjects with diabetic neuropathy receiving SB-509.
- Conditions
- Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Diabetic Polyneuropathy
- Trial name
- NCT00665145
- Testing
- SB-509
- Where
- 4 sites in United States
- Volunteers
- 23 people
- Sponsor
- Sangamo Therapeutics
Diabetic Neuropathies
An Efficacy and Safety Study of Carisbamate in the Treatment of Nerve Pain in Diabetics
The purpose of this study is to evaluate the safety, tolerability, and efficacy of carisbamate (800 and 1200 mg/day) in patients with diabetic neuropathic pain.
- Trial name
- NCT00870454
- Testing
- Pregabalin 300 mg/d, Carisbamate 800 mg/d, Carisbamate 1,200 mg/d
- Volunteers
- 386 people
- Sponsor
- SK Life Science, Inc.
Postoperative Pain
Safety, Efficacy, and Pharmacokinetics of SKY0402 Administered as a Nerve Block in Subjects Undergoing Bunionectomy
The primary objective of this study was to determine the appropriate dose of SKY0402 administered as a nerve block for the management of postoperative pain following bunionectomy.
- Trial name
- NCT01206595
- Testing
- SKY0402, Bupivacaine HCl
- Volunteers
- 58 people
- Sponsor
- Pacira Pharmaceuticals, Inc
Neuro ICU, Sub Arachnoid Hemorrhage
Comparison of Ultrasound Cerebral Perfusion Imaging With Routine Perfusion CT
The primary goal of neurocritical care is to prevent secondary brain injury, which worsens neurological outcomes. Because clinical monitoring is often insufficient due to the patient's condition and medical treatments, multimodal…
- Conditions
- Neuro ICU, Sub Arachnoid Hemorrhage, Neurological Complication, Cerebral Ischemia
- Trial name
- SCULPT (NCT07324421)
- Testing
- Ultrasound contrast agent (Contrast-enhanced ultrasound)
- Where
- France
- Volunteers
- 50 people
- Sponsor
- Resolve Stroke
Refractory Lupus Nephritis, Myasthaenia Gravis
A Long-Term Follow-Up Study for Participants Previously Treated With KYV-101
The purpose of this long-term follow-up (LTFU) study is to collect delayed adverse events (AEs) and understand the persistence of KYV-101 (autologous CAR T cell product; gene-modified product), in participants who have been…
- Conditions
- Refractory Lupus Nephritis, Myasthaenia Gravis, Stiff Person Syndrome, Rheumatoid Arthritis (RA)
- Trial name
- KYSA-4 (NCT07403188)
- Testing
- KYV-101
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Kyverna Therapeutics
Postoperative Pain
Study to Evaluate Analgesic Effect of IV Administration of Kappa Agonist CR845 For Hysterectomy Surgery
The primary purpose of this study is to determine if CR845 is effective in treating the pain associated with a laparoscopic hysterectomy.
- Trial name
- NCT01361568
- Testing
- CR845
- Where
- 18 sites in United States
- Volunteers
- 203 people
- Sponsor
- Cara Therapeutics, Inc.
Parkinson's Disease
Clinical Trial of Apomorphine Subcutaneous Infusion in Patients With Advanced Parkinson's Disease
The primary objective of the trial was to investigate the efficacy of apomorphine continuous subcutaneous infusion compared to placebo in Parkinson's Disease patients with motor fluctuations not well controlled on medical…
- Trial name
- TOLEDO (NCT02006121)
- Testing
- Apomorphine hydrochloride
- Where
- 20 sites in Austria, Denmark and 5 more
- Volunteers
- 107 people
- Sponsor
- Britannia Pharmaceuticals Ltd.
Diabetic Neuropathy, Painful, Diabetic Polyneuropathy
A Long-term Safety Study With Tapentadol ER and Oxycodone CR in Patients With Moderate to Severe Pain Due to Chronic, Painful Diabetic Peripheral Neuropathy (DPN)
The purpose of this study is to evaluate the safety profile of orally administered tapentadol ER dosages of 100 to 250 mg twice daily in patients with chronic, painful diabetic peripheral neuropathy (DPN) over long-term exposure…
- Trial name
- NCT01063868
- Testing
- Tapentadol extended release (ER), Oxycodone controlled release (CR)
- Where
- 23 sites in United States
- Volunteers
- 47 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Painful Diabetic Neuropathy
A Trial to Investigate Safety and Efficacy of SPM927 in Painful Diabetic Neuropathy
The primary purpose is to investigate the safety and efficacy of SPM927 in patients with Painful Diabetic Neuropathy
- Trial name
- NCT00861445
- Testing
- SPM927/Lacosamide
- Volunteers
- 119 people
- Sponsor
- UCB Pharma
Diabetic Neuropathies, Neuralgia
Pregabalin Peripheral Neuropathic Pain Study
To evaluate the efficacy of pregabalin, using a flexible, optimized dose schedule with dose adjustment based on Daily Pain Rating Scale (DPRS), compared to placebo in subjects with peripheral neuropathic pain.
- Trial name
- NCT00141219
- Testing
- pregabalin
- Where
- 10 sites in South Korea
- Volunteers
- 241 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Diabetic Neuropathies, Diabetes Mellitus
Treatment of Peripheral Neuropathy in Patients With Diabetes
The purpose of this protocol is to determine if an investigational drug is effective in treating nerve malfunction in diabetes.
- Trial name
- NCT00044421
- Testing
- Ruboxistaurin mesylate
- Where
- 71 sites in United States, Australia and 13 more
- Volunteers
- 400 people
- Sponsor
- Eli Lilly and Company
Fabry Disease
A Study to Evaluate Migalastat in Fabry Subjects With Amenable GLA Variant and Renal Disease
An Open-label Study to Evaluate the Safety and Pharmacokinetics of Migalastat HCl in Subjects with Fabry Disease and Amenable GLA Variants and Severe Renal Impairment (SRI) or End Stage Renal Disease (ESRD)
- Trial name
- NCT04020055
- Testing
- migalastat HCl 150 mg
- Where
- 12 sites in United States, Australia and 4 more
- Volunteers
- 14 people
- Sponsor
- Amicus Therapeutics
Growth Hormone Deficiency, Turner Syndrome
Predictive Markers in Growth Hormone Deficiency (GHD) and Turner Syndrome (TS) Children Treated With SAIZEN®
The study aims at identifying the predictive markers after one month of Saizen therapy in Growth Hormone Deficiency (GHD) and Turner Syndrome children.
- Trial name
- NCT00256126
- Testing
- Saizen
- Where
- 13 sites in Argentina, Australia and 11 more
- Volunteers
- 318 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Neuroblastoma, Rhabdomyosarcoma
Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors in Pediatric Patients
This is a Phase I, open-label, dose-escalation trial of JX-594 (Pexa-Vec) in pediatric patients with advanced/metastatic, unresectable solid tumors refractory to standard therapy and/or the patient does not tolerate standard…
- Conditions
- Neuroblastoma, Rhabdomyosarcoma, Lymphoma, Wilm's Tumor
- Trial name
- NCT01169584
- Testing
- Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- Jennerex Biotherapeutics
Down Syndrome (Trisomy 21), Edward's Syndrome (Trisomy 18)
Non-Invasive Determination of Fetal Chromosome Abnormalities
The overall significance of this study is to develop a laboratory developed test (LDT) to use a new marker in the maternal blood to better identify pregnancies that have a child with a chromosome abnormality such as Down syndrome…
- Conditions
- Down Syndrome (Trisomy 21), Edward's Syndrome (Trisomy 18), Patau Syndrome (Trisomy 13), Klinefelter Syndrome (47, XXY)
- Trial name
- NCT00891852
- Where
- 7 sites in United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Lenetix Medical Screening Laboratory
Diabetic Neuropathy, Pain
Spinal Cord Stimulation for Painful Diabetic Neuropathy
The purpose of this study is to evaluate Spinal Cord Stimulation (SCS) therapy in individuals who suffer from painful diabetic peripheral neuropathy.
- Conditions
- Diabetic Neuropathy, Pain, Peripheral Neuropathy
- Trial name
- DPN (NCT00487981)
- Testing
- Precision Spinal Cord Stimulation
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Boston Scientific Corporation
Parkinson's Disease, Parkinson Disease
Onset Motor Complications Using REQUIP CR (Ropinirole Controlled-release) As Add-on Therapy To L-dopa In Parkinson's
This study evaluates how effective a new formulation of a marketed drug is in increasing the time to onset of dyskinesia (abnormal twisting, writhing movements) in patients with Parkinson's Disease who have been taking levodopa…
- Conditions
- Parkinson's Disease, Parkinson Disease, Dyskinesias
- Trial name
- NCT00363727
- Testing
- ropinirole controlled-release (REQUIP CR) for RLS
- Where
- 69 sites in United States
- Volunteers
- 209 people
- Sponsor
- GlaxoSmithKline